Intravenous immune globulin in recurrent abortion

Area of Science:

• Immunology
• Reproductive Medicine
• Clinical Trials

Background:

• Habitual abortion is a concern, with immunotherapy using allogeneic leucocytes as a potential treatment.
• Intravenous immune globulin (IVIG) has been proposed as an alternative therapy for habitual abortion.
• Pilot studies suggested IVIG improved pregnancy outcomes in approximately 80% of treated patients.

Purpose of the Study:

• To evaluate the specific therapeutic effect of IVIG in patients with a history of habitual abortion.
• To differentiate potential pharmacological effects from placebo effects in IVIG treatment.
• To verify promising results from earlier pilot studies in a controlled setting.

Main Methods:

• A German randomized, double-blind, multicentre trial was conducted.
• IVIG was compared against human albumin 5% as a placebo.
• The study aimed to assess pregnancy outcomes in patients receiving IVIG versus placebo.

Main Results:

• The controlled trial did not verify a specific therapeutic effect of IVIG.
• No significant difference in pregnancy outcomes was observed between the IVIG group and the placebo group.
• The success rate in treated patients needs to be interpreted considering the spontaneous pregnancy success rate of 60%.

Conclusions:

• The specific therapeutic effect of IVIG for habitual abortion could not be verified in this controlled trial.
• Further controlled studies are required to definitively assess IVIG's efficacy and rule out placebo effects.
• Results from ongoing studies, including one in the USA, are anticipated to provide further insights.